Recent Updates — IDXG

Interpace Biosciences announced preliminary, unaudited third quarter 2026 revenue expected to range from $10.1 million to $10.4 million. This represents approximately 11% to 14% growth compared with the second quarter of 2026 and 15% to 18% year-over-year growth against the third quarter of 2025. The figures are preliminary, subject to closing procedures and independent review, and actual results may differ materially. Interpace Biosciences operates in the molecular diagnostics industry, providing specialized tests for personalized medicine.

Interpace Biosciences reported second quarter 2026 revenue of $9.1 million, reflecting a 9% year-over-year increase on a pro forma basis after excluding its discontinued PancraGEN business. The company generated income from continuing operations of $0.3 million and Adjusted EBITDA of $0.7 million, with gross margins expanding to 62%. Thyroid test volume grew 6% while average revenue per test increased 3%. Additionally, the firm announced it will appoint a Chief Scientific Officer effective September 8, 2026, to lead scientific strategy and clinical development for its pancreatic cancer program. Interpace Biosciences operates in the molecular diagnostics industry, specializing in thyroid cancer testing through its ThyGeNEXT and ThyraMIR platforms.